ERBB4 and schizophrenia: In a study on mice, the use of spironolactone as an antagonist of NRG1‐ERBB4 signaling was associated with the improvement of working memory impairment by reversing the hyperphosphorylation of activated Erbb4 (NRG1 and its cognate receptor ERBB4 are considered as schizophrenia risk genes and altered NRG‐ERBB4 signaling is associated with positive, negative, and cognitive symptoms) (Wehr et al., 2017).